[Ossio in MassDevice] Ossio closes $38.5M Series C
Orthopedic fixation technology developer Ossio announced today that it closed a $38.5 million Series C financing round. Read...
Read MoreOct 17, 2022 | News Center
Orthopedic fixation technology developer Ossio announced today that it closed a $38.5 million Series C financing round. Read...
Read MoreAug 8, 2022 | News Center, Newsticker
WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Inc., a fast-growing orthopedic fixation technology company, announced today the U.S. launch and first commercial use of OSSIOfiber® Suture Anchors, expanding patient access to the company’s growing portfolio of bio-integrative implants for use in foot/ankle, shoulder, knee, hand/wrist and elbow surgery. Read more...
Read MoreMar 29, 2022 | News Center, Newsticker
Ossio announced today that it received the third FDA clearance for its OssioFiber product family in recent months. Read...
Read MoreFeb 2, 2021 | News Center
OSSIO Inc.’s OSSIOfiber compression screw portfolio received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for maintenance of alignment and fixation of bone fractures, comminuted fractures, fragments, osteotomies, arthrodesis, and bone grafts of the upper extremity, fibula, knee, ankle, and foot in the presence of appropriate brace and/or immobilization. Read...
Read MoreNov 12, 2020 | News Center
Ossio, Inc.’s OSSIOfiber Compression Screws have received 510(k) clearance from the FDA. The screws are indicated for “maintenance of alignment and fixation of bone fractures, comminuted fractures, fragments, osteotomies, arthrodesis, and bone grafts, of the upper extremity, fibula, knee, ankle and foot in the presence of appropriate brace and/or immobilization,” according to FDA clearance documents. Read...
Read More